Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study

Marcus A. Bachhuber, R. Gross

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

Original languageEnglish (US)
Pages (from-to)1038-1040
Number of pages3
JournalInternational Journal of Tuberculosis and Lung Disease
Volume13
Issue number8
StatePublished - Aug 2009
Externally publishedYes

Fingerprint

Isoniazid
HIV
Mortality
Proteins
Therapeutics
Meta-Analysis
Cause of Death
Tuberculosis

Keywords

  • HIV
  • Isoniazid
  • Mortality
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Mortality benefit of isoniazid preventive therapy in HIV-positive persons : A simulation study. / Bachhuber, Marcus A.; Gross, R.

In: International Journal of Tuberculosis and Lung Disease, Vol. 13, No. 8, 08.2009, p. 1038-1040.

Research output: Contribution to journalArticle

@article{5e150149bc644f4da5dab7de13238061,
title = "Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study",
abstract = "A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95{\%} credibility interval 0.6-0.95).",
keywords = "HIV, Isoniazid, Mortality, Tuberculosis",
author = "Bachhuber, {Marcus A.} and R. Gross",
year = "2009",
month = "8",
language = "English (US)",
volume = "13",
pages = "1038--1040",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "8",

}

TY - JOUR

T1 - Mortality benefit of isoniazid preventive therapy in HIV-positive persons

T2 - A simulation study

AU - Bachhuber, Marcus A.

AU - Gross, R.

PY - 2009/8

Y1 - 2009/8

N2 - A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

AB - A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

KW - HIV

KW - Isoniazid

KW - Mortality

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=69149110279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149110279&partnerID=8YFLogxK

M3 - Article

C2 - 19723386

AN - SCOPUS:69149110279

VL - 13

SP - 1038

EP - 1040

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 8

ER -